SHORT COMMUNICATION
planning, and treatment during the pregnancy, postpartum and breastfeeding period in patients with antiphospholipid syndrome
Submission date: 2013-12-19
Acceptance date: 2014-02-10
Online publication date: 2014-03-23
Publication date: 2014-02-28
Reumatologia 2014;52(1):30-37
KEYWORDS
TOPICS
ABSTRACT
The antiphospholipid syndrome (APS) is an interdisciplinary condition with a clinical picture in which thrombotic complications and obstetric failures play the most significant role. It has been demonstrated on the basis of multicentre clinical observations that the most common pregnancy-related complications in the course of APS include: recurrent miscarriage in the first trimester of pregnancy, pregnancy loss in the second and third trimester of pregnancy, early preeclampsia and preterm delivery. Any APS female patient planning a pregnancy should be advised about the risk of complications which may occur in the course of pregnancy. The treatment of pregnant APS patients should be conducted by a multidisciplinary team including specialists in rheumatology, obstetrics, and in justified cases also in haematology. The most important element of the pregnant APS patient management is secondary thromboprophylaxis with low dose aspirin and heparins. The introduction of hydroxychloroquine is recommended in patients with systemic lupus erythematosus. The visits should take place every 4 weeks and starting from week 26–28 of pregnancy every 1–2 weeks. The patients should be strictly monitored for signs of preeclampsia and/or thrombosis.
REFERENCES (38)
1.
Cohen D, Berger SP, Steup-Beekman GM, et al. Diagnosis and management of the antiphospholipid syndrome. BMJ 2010; 340: c2541.
2.
Branch W; Obstetric Task Force. Report of the Obstetric APS Task Force: 13th International Congress on Antiphospholipid Antibodies, 13th April 2010. Lupus 2011; 20: 158-164.
3.
Vinatier D, Dufour P, Cosson M, Houpeau JL. Antiphospholipid syndrome and recurrent miscarriages. Eur J Obstet Gynecol Reprod Biol 2001; 96: 37-50.
4.
Simchen MJ, Dulitzki M, Rofe G, et al. High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome. Acta Obstet Gynecol Scand 2011; 90: 1428-1433.
5.
Ruffatti A, Calligaro A, Hoxha A, et al. Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. Arthritis Care Res (Hoboken) 2010; 62: 302-307.
6.
Lockshin MD, Kim M, Laskin CA, et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012; 64: 2311-2318.
7.
Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Euro-Phospholipid Project Group. Arthritis Rheum 2002; 46: 1019-1027.
8.
Alijotas-Reig J, Ferrer-Oliveras R; EUROAPS Study Group. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): a preliminary first year report. Lupus 2012; 21: 766-768.
9.
Wijetilleka S, Scoble T, Khamashta M. Novel insights into pathogenesis, diagnosis and treatment of antiphospholipid syndrome. Curr Opin Rheumatol 2012; 24: 473-481.
10.
Oku K, Amengual O, Atsumi T. Pathophysiology of thrombosis and pregnancy morbidity in the antiphospholipid syndrome. Eur J Clin Invest 2012; 42: 1126-1135.
11.
Di Prima FA, Valenti O, Hyseni E, et al. Antiphospholipid syndrome during pregnancy: the state of the art. J Prenat Med 2011; 5: 41-53.
12.
De Carolis S, Botta A, Santucci S, et al. Complementemia and obstetric outcome in pregnancy with antiphospholipid syndrome. Lupus 2012; 21: 776-778.
13.
Girardi G, Yarilin D, Thurman JM, et al. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med 2006; 203: 2165-2175.
14.
Kwak JY, Beer AE, Kim SH, Mantouvalos HP. Immunopathology of the implantation site utilizing monoclonal antibodies to natural killer cells in women with recurrent pregnancy losses. Am J Reprod Immunol 1999; 41: 91-98.
15.
Velayuthaprabhu S, Matsubayashi H, Sugi T, et al. Expression of apoptosis in placenta of experimental antiphospholipid syndrome mouse. Am J Reprod Immunol 2013; 69: 486-494.
16.
Di Simone N, Di Nicuolo F, D’Ippolito S, et al. Antiphospholipid antibodies affect human endometrial angiogenesis. Biol Reprod 2010; 83: 212-219.
17.
Girardi G, Mackman N. Tissue factor in antiphospholipid antibody-induced pregnancy loss: a pro-inflammatory molecule. Lupus 2008; 17: 931-936.
18.
Danza A, Ruiz-Irastorza G, Khamashta M. Antiphospolipid syndrome in obstetrics. Best Pract Res Clin Obstet Gynaecol 2012; 26: 65-76.
19.
Ernest JM, Marshburn PB, Kutteh WH. Obstetric antiphospholipid syndrome: an update on pathophysiology and management. Semin Reprod Med 2011; 29: 522-539.
20.
Martínez-Zamora MÁ, Cervera R, Balasch J. Recurrent miscarriage, antiphospholipid antibodies and the risk of thromboembolic disease. Clin Rev Allergy Immunol 2012; 43: 265-274.
21.
Rand JH, Wu XX, Quinn AS, et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood 2010; 115: 2292-2299.
22.
Wozniacka A, Lesiak A, Narbutt J, et al. Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients. Lupus 2006; 15: 268-275.
23.
Lesiak A, Narbutt J, Sysa-Jedrzejowska A, et al. Effect of chloroquine phosphate treatment on serum MMP-9 and TIMP-1 levels in patients with systemic lupus erythematosus. Lupus 2010; 19: 683-688.
24.
Check JH. The use of heparin for preventing miscarriage. Am J Reprod Immunol 2012; 67: 326-333.
25.
D’Ippolito S, Marana R, Di Nicuolo F, et al. Effect of low molecular weight heparins (LMWHs) on antiphospholipid antibodies (aPL)-mediated inhibition of endometrial angiogenesis. PLoS One 2012; 7: e29660.
26.
Mehta TP, Smythe MA, Mattson JC. Strategies for managing heparin therapy in patients with antiphospholipid antibody syndrome. Pharmacotherapy 2011; 31: 1221-1231.
27.
de Jesus GR, dos Santos FC, Oliveira CS, et al. Management of obstetric antiphospholipid syndrome. Curr Rheumatol Rep 2012; 14: 79-86.
28.
Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet 2010; 376: 1498-1509.
29.
Le Thi Huong D, Wechsler B, Vauthier-Brouzes D, et al. The second trimester Doppler ultrasound examination is the best predictor of late pregnancy outcome in systemic lupus erythematosus and/or the antiphospholipid syndrome. Rheumatology (Oxford) 2006; 45: 332-338.
30.
Ruiz-Irastorza G, Khamashta MA. Antiphospholipid syndrome in pregnancy. Rheum Dis Clin North Am 2007; 33: 287-297.
31.
Galarza-Maldonado C, Kourilovitch MR, Pérez-Fernández OM, et al. Obstetric antiphospholipid syndrome. Autoimmun Rev 2012; 11: 288-295.
32.
Ruffatti A, Calligaro A, Del Ross T, et al. Risk-based secondary prevention of obstetric antiphospholipid syndrome. Lupus 2012; 21: 741-743.
33.
Xiao J, Xiong J, Zhu F, He L. Effect of prednisone, aspirin, low molecular weight heparin and intravenous immunoglobulin on outcome of pregnancy in women with antiphospholipid syndrome. Exp Ther Med 2013; 5: 287-291.
34.
Bramham K, Thomas M, Nelson-Piercy C, et al. First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood 2011; 117: 6948-6951.
35.
Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet 2010; 376: 1498-1509.http://www.ncbi.nlm.nih.gov/pu...+ 2011%3B10%3A669-673.
36.
Scoble T, Wijetilleka S, Khamashta MA. Management of refractory anti-phospholipid syndrome. Autoimmun Rev 2011; 10: 669-673.
37.
Alijotas-Reig J. Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management. Lupus 2013; 22: 6-17.
38.
Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006; 4: 295-306.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
